Compass Therapeutics, Inc. (CMPX) Balance Sheet

The rapid contraction in cash reserves suggests that the company's operational runway is narrowing, which may necessitate near-term capital market intervention. Investors should monitor the current ratio, which, while appearing high at 15.02, is largely a function of low current liabilities rather than an abundance of liquid assets.

The low leverage profile appears consistent with a pre-revenue biotech firm that lacks the stable cash flows required to service interest-bearing debt. While this limits insolvency risk from creditors, it underscores the company's total reliance on equity markets to sustain its operations.

The absence of goodwill or significant tangible assets suggests that the company's valuation is almost exclusively tied to the success of its bispecific antibody platform. The lack of commercial-scale manufacturing assets implies that any future product launch would likely require significant capital expenditure or reliance on third-party contract manufacturers.

The consistent decline in retained earnings serves as a proxy for the total capital consumed by the R&D-heavy business model. This erosion suggests that shareholders are bearing the full cost of clinical development, with the potential for further dilution as the company seeks to replenish its equity base.